autologous tumor-infiltrating lymphocytes (Shanghai 10th People's Hospital)

This autologous tumor-infiltrating lymphocyte (TIL) therapy is a cell-based immunotherapy developed and investigated at Shanghai 10th People's Hospital for the treatment of relapsed or refractory gynecologic malignancies, including ovarian, cervical, and endometrial cancers. The therapeutic process involves the surgical extraction of TILs from a patient's tumor tissue, followed by large-scale ex vivo expansion. Once expanded, the polyclonal T cells are re-infused into the patient following a non-myeloablative lymphodepletion regimen typically consisting of cyclophosphamide and fludarabine or hydroxychloroquine. The therapy is designed to leverage the patient's own immune system to recognize and eliminate cancer cells by targeting a broad spectrum of tumor-associated antigens. Some versions of the therapy are genetically modified to express membrane-bound Interleukin-7 (mbIL-7) to enhance T-cell persistence and anti-tumor activity, and the treatment is frequently evaluated in combination with PD-1 checkpoint inhibitors such as sintilimab.

Other names

Tumor Infiltrating Lymphocytes (TIL)TIL therapy (Shanghai 10th People's Hospital)autologous TILs